Asset profile
Gefitinib
Small molecule
Evidence outlook
Approved: Non-Small Cell Lung Cancer (label: metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitutions)
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
102 competitors in this universe: 41 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Gefitinib: this drug | Approved | Small molecule | EGFR | ||
| Lazertinib | Approved | Small molecule | EGFR | ||
| Osimertinib (Tagrisso) | Approved | Small molecule | EGFR | ||
| Sunvozertinib | Approved | Small molecule | EGFR | ||
| Alflutinib | Phase 3 | Small molecule | EGFR | ||
| Almonertinib | Phase 3 | Small molecule | EGFR | ||
| Befotertinib | Phase 3 | Small molecule | EGFR | ||
| BPI-7711 | Phase 3 | Small molecule | EGFR | ||
| CPO301 | Phase 3 | Antibody–drug conjugate | EGFR | ||
| FHND9041 | Phase 3 | Small molecule | EGFR | ||
| Icotinib | Phase 3 | Small molecule | EGFR | ||
| JMT101 | Phase 3 | Monoclonal antibody | EGFR | ||
| Limertinib | Phase 3 | Small molecule | EGFR, EGFR T790M (resistant mutant, selective over wild-type EGFR) | ||
| PLB1004 | Phase 3 | Small molecule | EGFR | ||
| SH-1028 | Phase 3 | Small molecule | EGFR | ||
| TY-9591 | Phase 3 | Small molecule | EGFR |
…and 87 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
35 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
October 2026 (1)
What to watch
2027 (1)
July 2027 (1)
What to watch
2028 (1)
March 2028 (1)
What to watch
2030 (1)
October 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.